AbbVie's elagolix on a great roll in its PH3 trials

Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six.

Shire groups up with Microsoft and EUORORDIS to work on a rare disease project

On average its rare disease patients around half of whom are children have to wait for five years before they receive the correct diagnosis for their condition.

Study claims the Importance of familiarizing the risks and benefits of phase 1 trials in pediatric cancer

On average, 1 in 10 children who enroll in pediatric phase 1 cancer trials are improved after the trial, and 1 in 50 die from drug-related complications.

The Health Industry Summit (tHIS) EXPO and Congress is a global umbrella event for Asia's pharmaceutical and medical industries, the region's fastest growing health market.

It brings together CMEF, PharmChina and API China in one place at the same time, providing complete coverage of the health industry.

For more information Click Here

Biotech uses New Technology to fight Cardiovascular Diseases

Despite significant technological advances in technology, cardiovascular diseases remain the number one cause of death globally. CVDs are a group of disorders of both the heart and blood...

Aimmune's peanut succeeds at phase 3 trials

U.S. drug developer Aimmune Therapeutics said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.

For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
or
call to: + 91 88268 49084

If you like to receive our latest Media Pack 2018 / Editorial Calender please click here

For the latest visit: www.worldpharmatoday.com